TrialBMC infectious diseases2023

Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002-an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults.

Guiling Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.